

Norway-Oslo: Vaccines
OJ S 13/2016 20/01/2016
Contract notice
Supplies

Directive 2004/18/EC

Section I: Contracting authority

I.1. Name and addresses

Official name: Nasjonalt Folkehelseinstitutt (FHI) [The Norwegian Institute of Public Health]
National registration number: 983744516
Postal address: Lovisenberggata 8
Town: Oslo
Postal code: 0456
Country: Norway
Contact person: Procurement unit
For the attention of: Ole Andreas Fuglesang
E-mail: ole.andreas.fuglesang@fhi.no
Telephone: +47 21077000

Internet address(es):

General address of the contracting authority: <http://www.fhi.no>
Address of the buyer profile: <https://kgv.doffin.no/ctm/Supplier/CompanyInformation/Index/1063>
Electronic access to information: <https://kgv.doffin.no/ctm/Supplier/Documents/Folder/139551>

Additional information can be obtained from:

the abovementioned address

Specifications and additional documents (including documents for competitive dialogue and a dynamic purchasing system) can be obtained from:

the abovementioned address

Tenders or requests to participate must be submitted: the abovementioned address

I.2. Type of the contracting authority

National or federal agency/office

I.3. Main activity

Health

I.4. Contract award on behalf of other contracting authorities

The contracting authority is purchasing on behalf of other contracting authorities: no

Section II: Object of the contract

II.1. Description

II.1.1. Title attributed to the contract by the contracting authority

HPV-vaccine for vaccination of women up to 26 years of age.

II.1.2. Type of contract and place of performance or delivery

Supplies

Purchase

Main site or place of performance: Oslo.

NUTS code NO0 Norge

II.1.3. Information about a framework agreement or a dynamic purchasing system

The procurement involves the establishment of a framework agreement

II.1.4. Information about framework agreement

Framework agreement with a single operator

Duration of the framework agreement

Duration in years: 2

Estimated total value of purchases for the entire duration of the framework agreement

Estimated value excluding VAT:

Range: between 27 000 000 and 61 000 000 NOK

II.1.5. Short description of the contract or purchase(s)

The objective of the procurement is to enter into framework agreement for the delivery of HPV vaccine for the vaccination of women up to 26 years of age. The vaccination of this group is a one-off measure, with a duration of two years. Start up for the vaccination is anticipated to be August 2016.

Acquiring vaccination of 6 sets corresponds to offering vaccine to 6 x 30 000 women = 180 000 women.

There is uncertainty surrounding the number of doses as it is dependent on how many women choose to be vaccinated (vaccine coverage).

As a result of this, the volume of the framework agreement spans from 20 % of the estimated coverage to 45 % of the estimated coverage. With three doses per person, this is equivalent to a volume of approx. 108 000 (minimum) — 243 000 doses (maximum). In accordance with the contract, the Contracting Authority is obliged to purchase the minimum volume. Call offs beyond the minimum volume will be dependent on budget coverage and what vaccine coverage is achieved.

II.1.6. CPV code(s)

33651600 Vaccines

II.1.7. Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: yes

II.1.8. Lots

This contract is divided into lots: no

II.1.9. Information about variants

Variants will be accepted: no

II.2. Scope of the procurement

II.2.1. Total quantity or scope

There is uncertainty surrounding the number of doses as it is dependent on how many women choose to be vaccinated (vaccine coverage).

As a result of this, the volume of the framework agreement spans from 20 % of the estimated coverage to 45 % of the estimated coverage. This is equivalent to a volume of approx. 108 000 (minimum) — 243 000 doses (maximum).

The calculation of the procurement's value is based on an estimated price per dose. As a result of this, the calculation of the procurement's value is uncertain.

Estimated value excluding VAT:

Range: between 27 000 000 and 61 000 000 NOK

II.2.2. Information about options

Options: no

II.2.3. Information about renewals

This contract is subject to renewal: no

II.3. Duration of the contract or time limit for completion

Start 8.4.2016. Completion 8.4.2018

Section III: Legal, economic, financial and technical information

III.1. Conditions related to the contract

III.1.1. Deposits and guarantees required

III.1.2. Main financing conditions and payment arrangements and/or reference to the relevant provisions governing them

III.1.3. Legal form to be taken by the group of economic operators to whom the contract is to be awarded

III.1.4. Contract performance conditions

The performance of the contract is subject to particular conditions: yes

Description of particular conditions: For 2016, the tenderer undertakes to deliver at least 27 000 doses by 1.8.2016. (Supply agreement point 3.6)

Resale. After written agreement with the supplier, The Norwegian Institute of Public Health can resell delivered but non distributed vaccine doses when the vaccination is considered carried out. (Supply agreement point 15, 15.1).

III.2. Conditions for participation

III.2.1. Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers

List and brief description of conditions: The tenderer must have the affairs in order with respect to the payment of tax, employer contribution and value added tax (VAT).

The following must be submitted:

'Certificate for tax and VAT' issued by the Tax Collector or The Norwegian Tax Administration. The certificate shall not be more than six months when calculated from the tender deadline expiry.

The tenderer must be a legally established company.

Documentation: Company registration certificate.

III.2.2. Economic and financial ability

List and brief description of conditions: Tenderers shall have sufficient financial strength to comply with the contractual obligations.

Documentation requirement:

The service provider's approved annual accounts including notes with the Board's and auditor's reports from the last 2 years.

If the annual accounts for the last year are not finished before the tender deadline expires for this competition, the preliminary annual accounts for the last year shall also be attached.

The Contracting Authority reserves the right to carry out a credit assessment. Financial strength is evaluated in relation to turnover, operating profit margin, solidity and liquidity.

Commitment statement.

If the tenderer is dependent on other companies (groups, parent company, sister company, sub-suppliers, manufacturer etc.) to fulfil this qualification requirement, the tenderer must also deliver the above named documentation for the sub-supplier.

III.2.3. Technical and professional ability

List and brief description of conditions:

Tenderers shall have good implementation ability.

Documentation requirement:

Live of the most relevant deliveries during the last three years, including information about the volume, dates and the name of the recipient.

The tenderer shall have sufficient delivery capacity to deliver a minimum of 121 500 doses of HPV vaccine per year.

Documentation requirement:

The tenderers shall submit confirmation that the tenderer (and the sub-tenderer, cf. point 2.1.5 of the tender documentation) has the capacity to deliver at least 121,500 doses per year to the Contracting Authority.

The tenderer shall have a good and relevant quality assurance system for this type of delivery.

Documentation requirement:

A concise description of the overall quality assurance system that the service provider will use for this contract.

Either: A certificate of the company's quality assurance system issued by independent bodies confirming that the tenderer meets certain quality assurance standards, for example NS-EN ISO 9001:2015, or equivalent

Or: Instead of a certificate, other verifiable quality control systems are acceptable where relevant procedures, certificates and deviation/ improvement work emerges.

The supplier shall have the necessary licences. The offered vaccine must be produced by a manufacturer holding authorisation from the relevant authorities in the EU/EEA to manufacture drugs. If the tenderer does not manufacture the vaccine itself, the tenderer must have the necessary authorisation from the relevant authorities in the EU/EEA to trade in pharmaceuticals. If the vaccine is imported, the import licence that covers the offered vaccine must be presented.

Documentation requirement:

- Copy of the manufacturing licence in the manufacturing country, or
- Copy of the sales licence from the relevant authority.
- Copy of the wholesaler or manufacturer licence in Norway.

III.2.4. Information about reserved contracts

III.3. Conditions specific to services contracts

III.3.1. Information about a particular profession

Execution of the service is reserved to a particular profession: no

III.3.2. Information about staff responsible for the performance of the contract

Obligation to indicate the names and professional qualifications of the staff assigned to performing the contract: no

Section IV: Procedure

IV.1. Type of procedure

IV.1.1. Type of procedure

Open

IV.1.2. Information about the limits on the number of candidates to be invited

IV.1.3. Information about reduction of the number of solutions or tenders during negotiation or dialogue

IV.2. Award criteria

IV.2.1. Award criteria

The most economically advantageous tender in terms of Criteria below

1. Price. Weighting 60

2. Quality: including Effect and Security. Weighting 40

IV.2.2. Information about electronic auction

An electronic auction will be used: no

IV.3. Administrative information

IV.3.1. File reference number attributed by the contracting authority

15/2976

IV.3.2. Previous publication concerning this procedure

no

IV.3.3. Conditions for obtaining specifications and additional documents or descriptive document

Payable documents: no

IV.3.4. Time limit for receipt of tenders or requests to participate

29.2.2016 - 13:00

IV.3.5. Estimated date of dispatch of invitations to tender or to participate to selected candidates

IV.3.6. Languages in which tenders or requests to participate may be submitted

Danish. English. Swedish.

Other: Norwegian.

IV.3.7. Minimum time frame during which the tenderer must maintain the tender

Duration in days: 090 (from the date stated for receipt of tender)

IV.3.8. Conditions for opening of tenders

Date: 29.2.2016 - 13:10

Place: Official name: The Norwegian Institute of Public Health

National registration number: 983 744 516

For the attention of: Ole Andreas Fuglesang

The Archive Unit, sub-archive Myren.

Persons authorised to be present at the opening of tenders: no

Section VI: Complementary information

VI.1. Information about recurrence

This is a recurrent procurement: no

VI.2. Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds:
no

VI.3. Additional information

Commitment statements (sub-suppliers and other companies for example groups, parent company, sister company, manufacturer etc.).

If the tenderer is relying on other companies to meet one or more of the qualification requirements, adequate documentation should be provided to enable the sub-supplier to prove that the relevant requirement has been met. In addition, the tenderer must document that he will have authority over the necessary resources of the other company/companies. Such documentation can be provided by, for example, submitting a signed commitment statement from these companies.

Tenderers are requested to register their interest in the case on doffin.no Any additional information, questions and answers will be published on doffin.no and all who have registered their interest will receive automatic notification.

VI.4. Procedures for review

VI.4.1. Review body

VI.4.2. Review procedure

VI.4.3. Service from which information about the review procedure may be obtained

VI.5. Date of dispatch of this notice

18.1.2016